1. Introduction {#sec1}
===============

Breast cancer is detected either by clinical signs such as palpable tumour or in mammographic screening. In both cases biopsies are taken from the tumour to determine whether the tumour is benign or malign. If malignancy is detected, the patient will be scheduled for surgery within a few weeks. Before the surgery, sentinel node (SN) diagnostics is generally performed to examine the spread of cancer cells to axillary lymph nodes. The SN can be identified using a blue dye, a radioactive colloid, or a combination of the two \[[@B1], [@B2]\].

Microarray technology enables scientists to study thousands of genes simultaneously. The resulting molecular profile can be used to study complex multifactorial diseases such as breast cancer \[[@B3], [@B4]\]. Gene signatures have been shown to correlate with clinically relevant clinicopathological parameters and prognosis \[[@B5]--[@B7]\]. These molecular signatures may be used to predict the individuals for whom therapy is beneficial and spare unnecessary treatment for over 80% of the others \[[@B6], [@B8]--[@B10]\].

The time of procurement, which refers to the point of when the biopsies are taken \[[@B11]\] as well as the postoperative handling \[[@B12]\], has been found to be a confounding factors in microarray data analysis in breast cancer. Most of the previously published studies consist of tumour tissue taken in connection to surgery. Biopsies taken from the tumour, while the tumour is within the breast prior to any manipulation, must be as near to the true expression state as possible. In this study, we analyzed whether there are differences in genes expressed in preoperative biopsies obtained in connection with mammography and postoperative biopsies taken from the tumour immediately after its removal from the patient.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

This study includes 13 patients from which both a pre- and postoperative samples were available. Histopathological characteristics are listed in [Table 1](#tab1){ref-type="table"}. All of the patients had been operated with ablatio mammae (surgical removal of the entire breast). Sentinel node diagnostics using 99 m Tc-labelled colloids were performed in eleven patients as a part of the surgical procedure \[[@B13]\], while the remaining two underwent direct complete axillary dissection. No recurrence of disease has been observed so far for these patients, but the follow-up time is short. All women participating in this study have signed an informed consent and the study design is approved by the Regional Committee for Medical and Health Research Ethics (REK).

2.2. Tissue Collection {#sec2.2}
----------------------

Preoperative needle biopsies were obtained by an experienced radiologist using a 16 Gauge core needle device through a small skin incision in a sterile field. Three samples were processed for routine histological diagnosis while one sample for molecular analysis was put directly into RNAlater (Sigma Aldrich, St Louis, MO, USA). The postoperative samples were taken by the breast cancer surgeon upon removal of the breast and were preserved in RNAlater. The RNAlater-stabilised tissue samples were stored at −80°C. The time delay between the sampling of the pre- and postoperative specimens were 2--8 weeks.

2.3. RNA Isolation {#sec2.3}
------------------

RNA was prepared using the method of Wei and Khan \[[@B14]\] but modified to also include miRNA. Briefly, frozen tissue samples were homogenized in TriReagent (Ambion, Austin, TX, USA) using a 5 mm steal bead in a Mixer Mill MM301 (Retsch, Haan, Germany) at 30 Hz for 2 min. After phase separation with 0.2 vol chloroform, the aqueous phase (containing RNA) was mixed with 1.5 vol 100% ethanol and transferred to RNeasy Mini columns (Qiagen, Hilden, Germany). Further processing (including on-column DNase digestion) was per the manufacturer\'s protocol and the purified RNA was eluted with RNase-free water. RNA concentration was measured using NanoDrop ND-1000 UV-VIS Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and the RNA quality analyzed on a 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). The purified RNA was stored at −80°C.

2.4. Microarray Analysis {#sec2.4}
------------------------

mRNA amplification, labelling, and hybridization were done following the manufacturer\'s instructions (Agilent One-Color Microarray-Based Gene Expression Analysis; Version 5.7). Briefly, 500 ng RNA was amplified and labelled with Cy3 using the Quick Amp labelling kit and the labelled cRNA purified using the Qiagen RNeasy Mini Kit. Amplification and labelling efficiency were controlled on the NanoDrop before 1.65 *μ*g cRNA was fragmented and applied to Agilent Whole Human Genome 4 × 44 k microarrays (G4112F). After hybridisation for 17 h at 65°C the microarray slides were washed and scanned with the Agilent Microarray Scanner. Microarray data were extracted using Agilent Feature Extraction (v. 10.7.1.1) and further quantile normalized and analyzed using J-Express 2009 \[[@B15]\]. For expression values the gProcessedSignal from Feature Extraction were used and controls and bad spots were filtered with maximum 20% allowed missing values. The expression values were log2-transformed and missing values imputed using the LSImpute Adaptive method. Differential expression was analyzed using SAM as implemented in J-Express with 1000 permutations and only genes with false discovery rate (FDR) \< 2.5% were considered significant. The microarray data are available at the ArrayExpress Archive (<http://www.ebi.ac.uk/microarray-as/ae/>) accession number E-MTAB-470.

Gene functional classification of the significant genes was performed using DAVID \[[@B16], [@B17]\] and pathway analysis was done through the use of Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Redwood City, CA, USA).

2.5. Quantitative RT-PCR {#sec2.5}
------------------------

To confirm the results of the microarray experiment, qRT-PCR using TaqMan low density arrays (Applied Biosystems, Carlsbad, CA, USA) were performed using primer-probe pairs for 13 of the significant genes ([Table 2](#tab2){ref-type="table"}). The genes were selected to contain both up- and downregulated genes. 500 ng RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) per the manufacturer\'s instructions. Due to lack of material, qRT-PCR was only performed for ten of the sample pairs. The samples were further processed using TaqMan Gene Expression Master Mix (Applied Biosystems) and run on the 7900HT Real-Time PCR System (Applied Biosystems) as per the manufacturer\'s instructions. Relative changes in gene expression were analyzed using the ΔΔCt-method \[[@B18]\] with the preoperative sample as control sample for each pair. As endogenous controls the average of *GAPDH*, *18S*, and *ACTB* were used.

3. Results {#sec3}
==========

3.1. mRNA Expression {#sec3.1}
--------------------

RNA was isolated from matching samples taken both before and after breast cancer surgery of 13 patients. After filtering, expression data were available from 24,105 different probes representing 18,189 different genes. Comparing the gene expressions of the 13 pairs showed that there was relatively little difference between the pre- and postoperative samples (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"} and Supplementary Figure  1 available online at doi:10.5402/2012/450267). Paired significance analysis of microarrays (SAM) \[[@B19]\], however, showed differently expression for 235 probes with false discovery rate (FDR) \<2.5%, corresponding to 228 different genes (Supplementary Table  1) that separates the pre- and postoperative samples (Figures [1(c)](#fig1){ref-type="fig"} and [1(d)](#fig1){ref-type="fig"} and Supplementary Figure  2). The majority (201) of these genes were upregulated and only 27 were downregulated in the postoperative samples. The differentially expressed genes contained genes involved in early response such as*FOSB*, response to oxidative stress such as *DUSP1,9* as well as genes earlier identified as differentially expressed in cancer (*MAPK*,*MALAT1*,*RASD1*, etc) ([Table 3](#tab3){ref-type="table"}).

Gene functional classification in DAVID of the upregulated genes showed enrichment for four groups (kinase/phosphatase, Ras, negative regulation of transcription, and transmembrane) while the downregulated genes mainly correspond to transmembrane proteins ([Table 4](#tab4){ref-type="table"}). Gene function was also analyzed by Ingenuity Pathways Analysis (IPA) and includes "cellular movements," "connective tissue development and movement" and "cellular growth and proliferation" ([Figure 2](#fig2){ref-type="fig"}). IPA also identified molecular networks connecting several of the genes: *FOSB*, *ERK*, *MAPK3*, *CYR61*, and the *RAS*-genes ([Figure 3(a)](#fig3){ref-type="fig"}); *DUSP1*, *ERK1/2*, *P38MAPK*, *DUSP9*, and *RASD1* ([Figure 3(b)](#fig3){ref-type="fig"}); *CYR61* and *NFR*κ*B* ([Figure 3(c)](#fig3){ref-type="fig"}) amongst other (Supplementary Figure  3).

3.2. Quantitative RT- PCR Validation {#sec3.2}
------------------------------------

To confirm the results of the microarray experiment, qRT-PCR was performed using primer-probe pairs for the top significant genes. The genes were selected to contain both up- and downregulated genes. The microarray and the qRT-PCR results were in agreement with the following genes ([Figure 4](#fig4){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}): *ACTB, CYR61, DUSP1, EVI2b, FOSB, GAPDH*, and *RASD1*.

3.3. Histological Analysis versus Gene Expression Analysis {#sec3.3}
----------------------------------------------------------

Immunohistochemistry was performed on the pre- and the postoperative samples. Overall the tumour content in the two samples were comparable and there was no systematic bias ([Table 1](#tab1){ref-type="table"}), indicating that the gene expression as measured by microarray is comparable in the pairs. In addition, ER and PGR status for the pre- and postoperative specimen were similar ([Table 1](#tab1){ref-type="table"}).

4. Discussion {#sec4}
=============

Microarray studies have influenced breast cancer research over the last decade revealing breast cancer as a heterogeneous disease opening for individual treatment in a clinical perspective. Therefore, the results from microarray studies need to be validated. Multiple studies have generated different gene list and studied the reproducibility and correlation with prognosis \[[@B20]--[@B22]\]. Despite the difference in development of these signatures and the limited overlap in gene identity, they show similar prognostic performance, adding to the growing evidence that these prognostic signatures are of clinical importance \[[@B20]\]. There are two prospective ongoing studies, the MINDACT trial \[[@B23]\] in Europe and TAILORx \[[@B24]\] in USA which will evaluate the prognostic potential of this technology.

One important question may be if the differences in gene expressions are related to tumour biology or reflect the surgical trauma of the patient or the manipulation of the tumour tissue during the operative procedure or the time of specimen handoff. If altered gene expression is caused by such exogenous factors, the results may differ considerably between studies depending on the operative procedure and the time spent at the operation before taking the tissue samples. It is therefore important to evaluate if gene expression patterns differ between biopsies taken before and after surgical procedure. This has been done in our study with 13 patients and the gene list of 228 genes was dominated by stress-related genes like *CYR61*, *MALAT1*, *RASD1*, *CX3CL1*, *FOSB*, and *CYP2D6*. Some of these genes have been studied by others in relation to oxidative stress \[[@B25]--[@B27]\] and also psychological stress \[[@B28]\]. These genes have different functions all included in very important pathways with strong hubs such as *MAPK3*, *NFR*κ*B*, *FOS,* and *ERK*.

Upregulation of Fos has been associated with breast cancer in a number of studies \[[@B29]--[@B31]\]. The fos-gene family consists of 4 members: *FOS*, *FOSB*, *FOSL1*, and *FOSL2*. These genes encode leucine zipper proteins that can dimerise with proteins of the jun-family, and the Fos-proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. Another gene, *CYR61* (cysteine-rich, angiogenic inducer, 61), most strongly associated to differential expression in pre- and postoperative samples, belongs to the CCN-family \[[@B32]\] and mediates cell proliferation, survival, and apoptosis. Acting as an extracellular matrix-associated signalling molecule, *CYR61* promotes the adhesion of endothelial cells through interaction with the integrin *α*v*β*3 and augments growth factor-induced DNA synthesis in the same cell type \[[@B33]\]. In this aspect, it is both chemotactic and angiogenic, two properties important for tumour growth and vascularisation. *CYR61* is claimed to play a critical role in oestrogen, as well as growth factor-dependent breast tumour growth \[[@B34]\]. In our list of genes, *CYR61* is repeatedly connected in most of the involved pathways. Further studies will be necessary to confirm and explain this association.

It is of particular importance to take into consideration knowledge about gene expression differences in pre- and postoperative tissue samples in the case of treatment response studies in the neoadjuvant setting, when the first sample is frequently taken by biopsy and the second during operation. In a study comparing gene expression profiles before and after doxorubicin and cyclophosphamide neoadjuvant chemotherapy \[[@B35]\] one of the genes upregulated after the first chemotherapy treatment was *DUSP1*. Expression of this gene may be associated with resistance to further administration of chemotherapy. In our study *DUSP1* was one of the significantly upregulated genes in postoperative tissue. *DUSP1* is a stress response gene of the mitogen-activated protein (*MAP*) kinase phosphatase family and is located in the cytoplasm, mitochondria, and the nucleus. The gene has been shown to be overexpressed in human breast cancer \[[@B36]\] through different signalling pathways. One important pathway is in response to stress which is mediated in part through the p38 *MAPK* pathway. Later studies have implicated that *DUSP1* is controlled by p53 during cellular response to oxidative stress \[[@B37]\]. A similar discussion could be relevant on molecular profiling of inflammatory breast cancer \[[@B29]\], where *DUSP1* was also among the genes suggested to be useful diagnostic and prognostic markers. Our study suggests that such findings have to (1) demonstrate upregulation above the one observed here by us attributable to the pre- and postoperative factors and (2) that deregulation attributable to the pre- and postoperative factors is similar in the compared case/control or treatment arm groups.

In the present study, it is not possible to separate the effects of operative manipulation, anaesthesia, or the injection of radioactive substance to examine spread of cancer cells. For the latter, we should have had a biopsy after the application of radioactivity not before operation. However, both ethical and logistical considerations make collection of such a sample infeasible. Wong et al. \[[@B11]\] studied the effects of timing of fine-needle aspiration biopsies. Using hierarchical clustering analysis, they found 12 genes to be differentially expressed before and after surgery, which were in agreement with our study all fos-related. However, it was unclear whether any other treatment, like sentinel node, was given to patients between the two time points. It has been previously shown that both fine-needle aspiration biopsy and central core biopsy yield a similar quality and quantity of total RNA and that microarray profiles are mainly the same \[[@B38]\]. Microscopic cell counts have demonstrated that there are more stromal cells present in core biopsies compared to fine-needle biopsies \[[@B38]\], and the core biopsy is therefore needed for the complete histological examination.

Another confounding factor in the analysis of gene expression profiles of breast cancers is intratumour heterogeneity \[[@B39], [@B40]\]. Even though this study was not designed to analyze this, molecular subclassification \[[@B41]\] of the samples did in a few cases give different result for the pre- and postoperative samples ([Table 5](#tab5){ref-type="table"}). Interference from surrounding normal tissue is not likely since the overall gene expression profiles of the pre- and postoperative samples were very similar and distinct from that of adjacent normal tissue (Supplementary Figure 1), thus, suggesting true cases of intratumour heterogeneity.

As we have seen there are genes that are differently expressed between the pre- and postoperative samples. We compared our gene lists to some of the publically available gene list to see if there were any overlapping genes. The Oncotype DX consists of 21 genes, 16 cancer related genes, and 5 reference genes \[[@B42]\]. One of these is also found in our gene list which differs between pre- and postoperative samples, namely, *GRB7*, which is upregulated in the postoperative samples. *GRB7* was associated with an increased risk of recurrence in TNBC (tripple negative breast cancer) treated with adjuvant doxorubicin-containing chemotherapy, suggesting that *GRB7* or *GRB7*-dependent pathways may serve as potential biomarkers for therapeutic targets \[[@B43], [@B44]\]. We have shown that this gene is upregulated in the postoperative sample. Even though the gene has been well characterized *in vitro* \[[@B45]--[@B47]\], it is of interest that we find it in the list of genes separating pre- and postoperative samples.

We also wanted to compare the 70 genes listed in the Mammaprint which were based on the intrinsic gene list \[[@B6]\]. As with the Oncotype DX, there was only one single gene (*NDRG1*) in common for the 70 gene list in Mammaprint with our gene list separating pre- and postoperative samples. *NDRG1* (N-myc downstream-regulated gene 1) is a member of the N-myc downregulated gene family which belongs to the alpha/beta hydrolase superfamily. The protein encoded by this gene is a cytoplasmic protein involved in stress responses, hormone responses, cell growth, and differentiation. The encoded protein is necessary for p53-mediated caspase activation and apoptosis. Expression of this gene may be a prognostic indicator for several types of cancer (provided by RefSeq, May 2012). The gene is significantly upregulated in the postoperative samples of the present study. It is known to be induced by stress, through hypoxia \[[@B48]\], like many of the other genes mentioned above.

Low expression of *NDRG1* is correlated with poor clinical outcome in breast cancer \[[@B49]\]. It has also been shown that expression of *NDRG1* is downregulated upon estradiol stimulation, and its expression is correlated with favorable prognosis in breast cancer patients \[[@B50]\]. On the other hand, induction of its differentiation is considered a promising alternative or complementary to standard anticancer chemotherapy. One may speculate why this gene is upregulated in the postoperative samples. Stress is probably the cause, but since the gene is a positive predictive factor, can we then say that we place the tumor into a different prognostic group simply because of the stress of the procedure. Fotovati et al. \[[@B51]\] concluded that *NDRG1* could be used as a biomarker for differentiation of breast cancer for both diagnostic and therapeutic purposes. Still it is very important to be aware of at what material the gene is measured upon.

Our study shows the expression profiles found in the analyses of breast cancer tissue must be evaluated with caution. Different profiles may simply be result of differences in the surgical trauma and timing of when samples are taken, and not necessarily associated with tumor biology.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary Figure 1: Hierarchal clustering with all probes present on the array of the pre- and postoperative samples together with corresponding adjacent normal tissue shows overall similar expression profiles for the majority of the pre- and postoperative tumor pairs.

Supplementary Figure 2: Hierarchical clustering of the samples using the differently expressed genes (FDR \< 2.5%) separates the majority of the preoperative tumors from the corresponding postoperative tumors.

Supplementary Figure 3: Molecular network showing the interaction between all the 228 differently expressed genes. The gene identifiers and corresponding expression values were uploaded into in the Ingenuity Pathway Analysis. Networks were then algorithmically generated based on their connectivity in Ingenuity\'s Knowledge Base. Molecules are represented as nodes, and the biological relationship between two nodes is represented as an edge (line). The intensity of the node color indicates the degree of up- (red) or down- (green) regulation. Nodes are displayed using various shapes that represent the functional class of the gene product.

Supplementary Table 1: Significantly differently expressed genes between pre- and postoperative samples. All probes with FDR \< 2.5% ranked according to SAM. Systematic names shown in brackets.

###### 

Click here for additional data file.
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![Unsupervised (a) and supervised (c) CA plots of mRNA expression in pre- and postoperative breast cancer tumours, and their corresponding clustering maps (b, d). The samples are marked by their respective numbers followed by either B, which defines the preoperative samples, or T, which defines the postoperative samples. The unsupervised chart was made using all 18,189 genes (24,105 probes) expressed on the microarrayss whereas for the supervised only the 228 genes (235 probes) with FDR \< 2.5% from paired SAM were used.](ISRN.ONCOLOGY2012-450267.001){#fig1}

![The most significantly enriched biological categories as identified with Ingenuity Pathway Analysis. For each category −log(*P* value) is reported.](ISRN.ONCOLOGY2012-450267.002){#fig2}

![Most enriched molecular networks showing interactions between the significant genes (according to SAM)---(a) *FOSB*, *ERK*, *MAPK3*, *CYR61*, and the *RAS*-genes; (b) *DUSP1*, *ERK1/2*, *P38MAPK*, *DUSP9*, and *RASD1*; (c) *CYR61* and *NFR*κ*B*. The gene identifiers and corresponding expression values were uploaded into in the Ingenuity Pathway Analysis. Networks were then algorithmically generated based on their connectivity in Ingenuity\'s Knowledge Base. Molecules are represented as nodes, and the biological relationship between two nodes is represented as an edge (line). The intensity of the node colour indicates the degree of (red) up- or (green) downregulation. Nodes are displayed using various shapes that represent the functional class of the gene product.](ISRN.ONCOLOGY2012-450267.003){#fig3}

![Relative expression of selected genes on microarrays (upwards) and qRT-PCR (downwards). Values shown are mean expression ±SE. For easier comparison, both the microarray and qRT-PCR values were gene-centered.](ISRN.ONCOLOGY2012-450267.004){#fig4}

###### 

Histopathological characteristics of the patients included in the study.

  --------------------------------------------------------------------------------------------------------------
  Case   Age   Tumour\   TNM          Tumour\     Preoperative   Postoperative                              
               type\*                 size (cm)                                                             
  ------ ----- --------- ------------ ----------- -------------- --------------- ---- ---- ---- ----------- ----
  2      54    IDC       T2gr3N2M0    4.3         30             \+ (\>50)       −    \+   30   −           −

  3      42    IDC       T2gr3N0M0    4.8         40             −               −    −    60   −           −

  4      67    IDC       T2gr2N1M0    3.5         50             \+ (\>50)       \+   −    55   \+ (\>50)   \+

  5      82    IDC       T1cgr3N0M0   1.8         30             \+ (\>50)       \+   −    40   \+ (\>50)   \+

  6      52    IDC       T2gr3N3M0    2.0         5              −               −    \+   5    −           −

  7      68    IDC       T1cgr3N1M0   1.3         35             \+ (\>50)       −    \+   40   \+ (\>50)   \+

  8      76    IDC       T1cgr2N0M0   1.4         40             −               −    −    35   −           −

  9      70    IDC       T1bgr1N0M0   0.9         25             \+ (\>50)       \+   −    25   \+ (\>50)   \+

  10     77    IDC       T2gr3N1M0    2.6         50             \+ (\>50)       −    −    15   \+ (\>50)   −

  11     61    IDC       T2gr3N1M0    2.5         50             −               −    \+   40   −           −

  13     79    IDC       T2gr3N0M0    2.3         45             \+ (\>10)       −    \+   55   \+ (\>1)    −

  14     70    IDC       T2gr2N0M0    2.3         35             \+ (\>50)       \+   −    35   \+ (\>50)   \+

  15     68    ILC       T2gr2N0M0    2.5         50             \+ (\>50)       −         30   \+ (\>50)   \+
  --------------------------------------------------------------------------------------------------------------

\*IDC: infiltrating ductal carcinoma; ILC: infiltrating lobular carcinoma.

^†^ER: oestrogen receptor status; PR: progesterone receptor status; HER2: HER2 receptor status.

###### 

TaqMan assays used for validation qRT-PCR and correlation between the microarray and the qRT-PCR results. The *P* values given are for positive correlation. *r*: Pearson\'s product-moment correlation.

  -----------------------------------------------------------------------------------------
  Gene        Array probe ID   TaqMan assay ID   Task                 *r*      *P*
  ----------- ---------------- ----------------- -------------------- -------- ------------
  *18S*       NA               Hs99999901_s1     Endogenous control   NA       NA

  *ACTB*      A_23_P31323\     Hs99999903_m1     Endogenous control   0.904    1.7*E* − 4
              A_24_P226554\                                                    
              A_24_P226554\                                                    
              A_32_P137939                                                     

  *ANGEL2*    A_24_P28622      Hs00404357_m1     Target               0.238    0.254

  *CYP2D6*    A_23_P143734\    Hs02576167_m1     Target               0.262    0.232
              A_23_P155123                                                     

  *CYR61*     A_23_P46426\     Hs00155479_m1     Target               0.894    2.4*E* − 4
              A_24_P370946                                                     

  *DUSP1*     A_23_P110712     Hs00610256_g1     Target               0.983    1.7*E* − 7

  *DUSP9*     A_24_P417189     Hs00154830_m1     Target               −0.630   0.965

  *EVI2B*     A_23_P66694      Hs00272421_s1     Target               0.945    1.8*E* − 5

  *FOSB*      A_23_P429998     Hs00171851_m1     Target               0.749    0.006

  *GAPDH*     A_23_P13899      Hs99999905_m1     Endogenous control   0.632    0.025

  *MALAT1*    A_24_P497244     Hs00273907_s1     Target               0.332    0.174

  *MAPK3*     A_23_P37910      Hs00385075_m1     Target               −0.018   0.520

  *NFR*κ*B*   A_23_P24485      Hs00196269_m1     Target               −0.169   0.680

  *PTPRE*     A_24_P213494\    Hs00369944_m1     Target               0.413    0.118
              A_24_P213503                                                     

  *RASD1*     A_24_P348006\    Hs02568415_s1     Target               0.797    0.003
              A_23_P118392                                                     

  *TMEM19*    A_24_P358976     Hs00217586_m1     Target               0.248    0.245
  -----------------------------------------------------------------------------------------

###### 

Selected genes that are differently expressed between pre- and postoperative samples.

  Gene name      Agilent ID     Description                                                                                                                                                                         SAM    Fold Change                        
  -------------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ------------- ------------- ------ -------------
  *CX3CL1*       A_24_P390495   Chemokine (C-X3-C motif) ligand 1 (*CX3CL1*), mRNA (NM_002996)                                                                                                                      21     0             0             2.99   0.90--4.09
  *CYP2D6*       A_23_P143734   Cytochrome P450, family 2, subfamily D, polypeptide 6 (*CYP2D6*), transcript variant 1, mRNA (NM_000106)                                                                            18     0             0             1.65   0.58--3.55
  A_23_P155123   103            2.08                                                                                                                                                                                1.55   1.51          0.46--3.38           
  *CYR61*        A_23_P46426    Cysteine-rich, angiogenic inducer, 61 (*CYR61*), mRNA (NM_001554)                                                                                                                   163    1.75          1.65          4.07   0.61--12.88
  A_24_P370946   196            1.82                                                                                                                                                                                1.79   5.51          0.36--22.80          
  *DUSP1*        A_23_P110712   Dual specificity phosphatase 1 (*DUSP1*), mRNA (NM_004417)                                                                                                                          217    2.3           2.20          3.18   0.49--12.69
  *DUSP9*        A_24_P417189   Dual specificity phosphatase 9 (*DUSP9*), mRNA (NM_001395)                                                                                                                          7      0             0             2.12   1.15--2.88
  *FOSB*         A_23_P429998   FBJ murine osteosarcoma viral oncogene homolog B (*FOSB*), transcript variant 1, mRNA (NM_006732)                                                                                   203    2.11          2.01          2.79   0.96--24.26
  *MALAT1*       A_24_P497244   Metastasis associated lung adenocarcinoma transcript 1 (nonprotein coding) (*MALAT1*), noncoding RNA (NR_002819)                                                                    3      0             0             3.54   1.31--9.97
  *MAPK3*        A_23_P37910    Mitogen-activated protein kinase 3 (*MAPK3*), transcript variant 1, mRNA (NM_002746)                                                                                                42     1.70          1.30          2.01   0.40--2.55
  *NFR*κ*B*      A_23_P24485    nuclear factor related to kappaB binding protein (*NFR*κ*B*), transcript variant 2, mRNA (NM_006165)                                                                                183    1.95          1.79          1.61   0.63--3.25
  *RAB17*        A_23_P5778     *RAB17*, member RAS oncogene family (*RAB17*), mRNA (NM_022449)                                                                                                                     10     0             0             1.84   0.23--4.36
  *RASAL1*       A_23_P139600   RAS protein activator like 1 (GAP1 like) (*RASAL1*), mRNA (NM_004658)                                                                                                               140    2.04          1.65          1.46   0.38--2.41
  *RASD1*        A_23_P118392   RAS, dexamethasone-induced 1 (*RASD1*), mRNA (NM_016084)                                                                                                                            105    2.04          1.55          3.14   0.88--21.55
  A_24_P348006   27             0                                                                                                                                                                                   0      2.69          0.85--12.90          
  *RHOB*         A_23_P51136    ras homolog gene family, member B (*RHOB*), mRNA (NM_004040)                                                                                                                        16     0             0             1.99   0.51--2.96
  *RHOU*         A_23_P114814   ras homolog gene family, member U (*RHOU*), mRNA (NM_021205)                                                                                                                        122    1.75          1.55          2.68   0.71--3.65
  *RHOV*         A_23_P117912   Rho-related GTP-binding protein RhoV (Wnt-1 responsive Cdc42 homolog 2)(WRCH-2)(CDC42-like GTPase 2)(GTP-binding protein-like 2) (Rho GTPase-like protein ARHV) (ENST00000220507)   184    1.94          1.79          1.60   0.25--5.45

###### 

Gene functional classification (DAVID) of the differently expressed genes.

  ---------------------------------------------------------------------------------------------------------------------
  Gene name                              Agilent ID               Description
  -------------------------------------- ------------------------ -----------------------------------------------------
  Gene group 1                           Enrichment score: 2.11   

  Kinase/phosphatase                                              

                                                                  

  *DCAKD*                                A_24_P58331              Dephospho-CoA kinase domain containing

  *SIK2*                                 A_23_P138957             Salt-inducible kinase 2

  *ITPKC*                                A_23_P208369             Inositol 1,4,5-trisphosphate 3-kinase C

  *DAK*                                  A_23_P36129              Dihydroxyacetone kinase 2 homolog (*S. cerevisiae*)

  *RIPK4*                                A_23_P211267             Receptor-interacting serine-threonine kinase 4

  *CHKA*                                 A_23_P136135             Choline kinase alpha

  *DDR1*                                 A_23_P93311,\            Discoidin domain receptor tyrosine kinase 1
                                         A_24_P367289             

  *STK35*                                A_24_P940537             Serine/threonine kinase 35

  *ACTR3B*                               A_23_P123193             ARP3 actin-related protein 3 homolog B (yeast)

  *INO80*                                A_24_P39454              INO80 homolog (*S. cerevisiae*)

  *EPHA1*                                A_23_P157333             EPH receptor A1

  *BCR*                                  A_24_P15270              Breakpoint cluster region

  *CAMK1D*                               A_23_P124252             Calcium/calmodulin-dependent protein kinase ID

  *HISPPD2A*                             A_23_P205818             Histidine acid phosphatase domain containing 2A

                                                                  

  Gene group 2                           Enrichment score: 1.35   

  Ras                                                             

                                                                  

  *RHOB*                                 A_23_P51136              Ras homolog gene family, member B

  *RHOV*                                 A_23_P117912             Ras homolog gene family, member V

  *RASD1*                                A_24_P348006,\           RAS, dexamethasone-induced 1
                                         A_23_P118392             

  *RAB17*                                A_23_P5778               RAB17, member RAS oncogene family

  *RHOU*                                 A_23_P114814             Ras homolog gene family, member U

                                                                  

  Gene group 3                           Enrichment score: 1.26   

  Negative regulation of transcription                            

                                                                  

  *ARID5B*                               A_23_P97871              AT rich interactive domain 5B (MRF1-like)

  *COBRA1*                               A_23_P148150             Cofactor of BRCA1

  *TH1L*                                 A_24_P222126             TH1-like (Drosophila)

  *FOXD3*                                A_23_P46560              Forkhead box D3

  *EID2*                                 A_23_P365844             EP300 interacting inhibitor of differentiation 2

                                                                  

  Gene group 4                           Enrichment score: 0.42   

  Transmembrane                                                   

                                                                  

  *PQLC1*                                A_24_P181677             PQ loop repeat containing 1

  *RNF215*                               A_32_P420563             Ring finger protein 215

  *KIAA1305*                             A_23_P129005             KIAA1305

  *TMEM49*                               A_32_P9753               Transmembrane protein 49

  *F11R*                                 A_24_P319369             F11 receptor

  *RBM8A*                                A_23_P305335             Gonadotropin-releasing hormone (type 2) receptor 2

  *KIAA0922*                             A_23_P257250             KIAA0922

  *TSPAN12*                              A_23_P145984             Tetraspanin 12

  *DGCR2*                                A_24_P125881             DiGeorge syndrome critical region gene 2

  *PCDH1*                                A_23_P213359             Protocadherin 1

  *LMBRD2*                               A_32_P8952               LMBR1 domain containing 2

  *GPR65*                                A_23_P14564              G protein-coupled receptor 65

  *EVI2B*                                A_23_P66694              Ecotropic viral integration site 2B

  *RTF1*                                 A_24_P93741              RFT1 homolog (*S. cerevisiae*)

  *TMEM19*                               A_24_P358976             Transmembrane protein 19

  *GPR155*                               A_23_P335958             G protein-coupled receptor 155

  *OSMR*                                 A_24_P145134             Oncostatin M receptor

  *TMEM97*                               A_32_P201521             Transmembrane protein 97

  *PTPRE*                                A_24_P213503,\           Protein tyrosine phosphatase, receptor type, E
                                         A_24_P213494             
  ---------------------------------------------------------------------------------------------------------------------

###### 

Intrinsic subtypes of the tumours. Samples with all correlations \< 0.1 were not assigned to any subtype.

  ----------------------------------------------------------------------------------------------------------------------------------
  Patient\        Sample type    Score       Subtype                                                              
  no.                                                                                                             
  --------------- -------------- ----------- ----------- ----------- ------------ ----------- ------------------- ------------------
  2               Preoperative   −0.050      0.231       0.103       −0.191       −0.034      0.231               Luminal B

  Postoperative   −0.081         0.193       0.010       0.011       0.062        0.193       Luminal B           

  3               Preoperative   −0.465      0.213       0.215       −0.061       0.616       0.616               Basal-like

  Postoperative   −0.454         0.177       0.190       0.010       0.668        0.668       Basal-like          

  4               Preoperative   0.064       0.152       −0.058      −0.268       −0.085      0.152               Luminal B

  Postoperative   0.085          0.063       0.017       −0.271      −0.227       0.085       NA                  

  5               Preoperative   −0.001      0.032       −0.028      0.014        −0.116      0.032               NA

  Postoperative   −0.050         0.088       −0.061      −0.056      −0.079       0.088       NA                  

  6               Preoperative   −0.454      0.067       0.477       −0.017       0.374       0.477               ERBB2

  Postoperative   −0.576         0.096       0.531       −0.015      0.410        0.531       ERBB2               

  7               Preoperative   0.234       0.031       −0.165      −0.212       −0.224      0.234               Luminal A

  Postoperative   0.123          −0.115      −0.106      0.067       −0.185       0.123       Luminal A           

  8               Preoperative   −0.117      −0.011      0.222       −0.066       0.031       0.222               ERBB2

  Postoperative   −0.066         −0.060      0.144       −0.065      −0.039       0.144       ERBB2               

  9               Preoperative   −0.127      −0.189      0.149       0.188        0.055       0.188               Normal-like

  Postoperative   −0.040         −0.220      0.077       0.266       0.005        0.266       Normal-like         

  10              Preoperative   0.032       0.039       −0.025      −0.085       −0.138      0.039               NA

  Postoperative   −0.003         0.218       −0.082      −0.201      −0.035       0.218       Luminal B           

  11              Preoperative   −0.269      0.260       0.242       −0.163       0.217       0.260               Luminal B

  Postoperative   −0.147         0.292       0.132       −0.174      0.086        0.292       Luminal B           

  13              Preoperative   −0.266      **0.130**   0.166       −0.002       **0.211**   0.211               **Basal-like**\*

  Postoperative   −0.105         **0.246**   0.089       −0.197      **0.007**    0.246       **Luminal B**\*     

  14              Preoperative   **0.169**   −0.111      −0.142      **−0.017**   −0.170      0.169               **Luminal A**\*

  Postoperative   **0.068**      −0.175      −0.092      **0.196**   −0.026       0.196       **Normal-like**\*   

  15              Preoperative   0.356       −0.013      −0.328      −0.188       −0.338      0.356               Luminal A

  Postoperative   0.223          −0.065      −0.131      −0.094      −0.349       0.223       Luminal A           
  ----------------------------------------------------------------------------------------------------------------------------------

\*Different subtypes in the pre- and postoperative samples.

[^1]: Academic Editors: E. A. Rakha and S. Ran
